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1. SYSTEMIC SCLEROSIS 
 
1.1. DEFINITION AND GENERAL ASPECTS 
Systemic Sclerosis (SSc), or scleroderma, is a rare autoimmune 
disease that involves the connective tissue of skin and internal organs, 
with a remarkable heterogeneity in the clinical features and course of 
the disease, resulting in high morbidity and mortality. The disease is 
characterized by severe and diffuse endothelial cell damage and by 
overproduction and accumulation of collagen and other extracellular 
matrix proteins, resulting in thickening of the skin and fibrosis of the 
affected organs. The pathogenic mechanisms involve three main 
components: a) vascular dysfunction and injury, b) activation of the 
immune system and c) increased secretion of collagen by fibroblasts. 
Currently the standard classification criteria for SSc are the 1980 
preliminary criteria for the classification of SSc, suggested by the 
American College of Rheumatology. These criteria allow the 
identification of three different forms of the disease: localized 
cutaneous scleroderma, SSc and overlap syndromes [1]. 
Localized scleroderma is characterized only by skin involvement. The 
main subtypes are plaque morphea, linear scleroderma, generalized 
morphea, and pansclerotic morphea. With few exceptions, the disorder 
does not have systemic involvement, but it can cause considerable 
morbidity. These forms are more common in childhood and are rarely 
associated with systemic involvement, unlike SSc [2,3]. 
SSc is characterized by affecting the skin and various organs and 
apparatuses. Considering the cutaneous extension of fibrosis, two 
subsets of illness can be identified: limited SSc (lSSc) and diffuse SSc 
(dSSc) [4-8]. The limited form is characterized by thickening of the 
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skin of the face and of the distal part of the limbs. Usually, cutaneous 
sclerosis arises after a long history of Raynaud's phenomenon, which 
sometimes precedes the systemic disease for decades. Visceral 
involvement is usually present although delayed: pulmonary 
hypertension can complicate the course of the disease in 10-15% of 
cases only after 3 years after the onset of the disease. In 70-80% of the 
cases lSSc is associated with the presence of anti-centromeric 
antibodies. The diffuse form of SSc is characterized by a cutaneous 
thickening that involves also the proximal portions of the limbs and 
often also the trunk and abdomen. Usually cutaneous sclerosis appears 
simultaneously with Raynaud's phenomenon or a short while after its 
onset. Initial visceral involvement is frequent. dSSc is associated in 
30% of cases with the presence of autoantibodies against DNA 
topoisomerase-1 (Scl-70). 
There are also cases of Systemic Lupus Erythematosus, Rheumatoid 
Arthritis, Sjogren's Syndrome and other types of connectivitis which 
develop cutaneous and/or visceral sclerosis. In these cases, a diagnosis 
of Overlap Syndrome can be performed when the criteria for diagnosis 
of SSc and of another autoimmune disease are met.  
Rarely, in 1% of cases, SSc can manifest without cutaneous 
involvement; this is then defined as SSc without scleroderma [6]. 
Recently, because of the low sensitivity of the 1980 criteria, and as a 
result of advances in the knowledge of SSc, the ACR and the 
European League Against Rheumatism (EULAR) have established a 
committee to suggest a joint proposal for new classification criteria for 
SSc. The aims are to develop criteria that 1) encompass a broader 
spectrum of SSc including patients whose disease is in the early stage 
as well as those in the late stage; 2) include vascular, immunological 
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and fibrotic manifestations; 3) are simple enough to be used in daily 
clinical practice; and 4) are in accordance with the criteria used for 
diagnosis of SSc in clinical practice [9]. These criteria may be 
endorsed as inclusion criteria for SSc studies. However, such criteria 
need to be validated in different populations before accepted in routine 
practice. 
 
1.2. EPIDEMIOLOGY 
The epidemiology of SSc is difficult to estimate. Varying prevalence 
and incidence rates of SSc have been reported due to the differences in 
the geographical area surveyed, the definition of the disease and the 
method of case ascertainment [10]. It is estimated that SSc has a 
prevalence between 50 and 300 cases per million inhabitants and an 
incidence ranging from 2.3 to 22.8 cases per million inhabitants per 
year in the general population [11]. 
The disease shows a marked predilection for the female sex, with a 
female/male ratio varying from 3:1 to 14:1 according to different 
studies. The onset of the disease can occur at any age; however 
subjects between the third and fifth decade of life are preferentially 
hit. Higher incidence and a younger age of onset are reported among 
African-Americans [12]. The latter have also a greater probability of 
developing diffuse cutaneous disease and pulmonary fibrosis; 
generally they have a worse prognosis than Caucasians [7].  
 
1.3. AETIOPATHOGENESIS 
SSc is a disease with sporadic onset and an aetiology which is not yet 
fully known. Besides genetic factors, various environmental factors 
may play an important role in the aetiopathogenesis of the disease. We 
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still lack an overall view of the process which eventually leads to 
sclerodermic damage. In the last few decades research has made 
considerable progress, trying to have a deeper inside into the three 
fundamental aspects of the disease: the vasculopathy; the alterations 
of cellular and humoral immune response; the excessive deposition of 
collagen and other macromolecules in the skin and in the target 
organs. One of the objectives of the present study is to try to identify 
initial events that eventually lead to the onset of the disease.  The 
comprehension of these pathogenetic aspects will enable us to identify 
new potential therapeutic targets. 
 
1.4. GENETIC FACTORS 
The role of genetic factors is supported by the fact that different cases 
have been observed in the same family, by the frequency of SSc is 
higher in families already suffering from other autoimmune 
pathologies, and by the greater risk of developing the disease in 
certain ethnic groups than in others. Twin studies have highlighted a 
greater probability of developing the disease among monozygote 
twins compared with dizygote twins, although with low concordance 
percentages (lower than 5%) [7]. Various studies have shown that SSc 
is associated with particular gene polymorphisms which code for 
cytokines and their receptors, chemokines and proteins of the 
extracellular matrix [13]. Furthermore, there is evidence of association 
between certain class II histocompatibility antigens, presentation of 
the disease and autoantibody structure [14]. 
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1.5. ENVIRONMENTAL FACTOR 
Environmental factors may play a role in triggering the disease on 
predisposing genetic background. Recent studies underline the 
importance of epigenetic modifications (methylation, acetylation, 
phosphorylation, sumoylation, microRNA) [15] that may link genes 
and environment in the pathogenesis of SSc.  
The principal environmental factors involved are: viruses, drugs, 
radiation and chemicals. 
The hypothesis that infectious agents may be involved in the 
pathogenesis of the disease is based on different mechanisms; the 
most studied mechanism is the presence of a molecular mimicry 
between autoantigens and proteins of viral origin. It is interesting to 
note that there is a certain structural similarity between retroviral 
proteins and topoisomerase I, an antigen recognized by anti-Sc1-70 
autoantibodies. It has emerged that the human Cytomegalovirus 
(HCMV) may contribute to the onset of SSc through its ability to 
infect endothelial cells and to induce cell activation and apoptosis.  
Patients affected by SSc present antibodies directed against the 
HCMV derived protein UL94; such antibodies are able to induce 
apoptosis of human endothelial cells and to stimulate fibroblast 
proliferation: two typical aspects of SSc [16-19]. 
Occupational chemicals which could play a role in the onset of SSc 
are: silica dust, polyvinyl chloride, trichloroethylene, organic solvents. 
Indications have also been reported for pesticides, hair tinctures and 
industrial fumes [20].  Cigarette smoke seem not associated with SSc; 
however, exposure to cigarette smoke is capable of aggravating and 
accelerating the course of sclerodermic vasculopathy and lung 
involvement. 
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Drugs correlated with the development of SSc-like syndromes are 
bleomycin (a fibrosing agent), pentazocine, cocaine and fenfluramine, 
which is associated with the onset of pulmonary hypertension. Even 
silicone prosthetic mammary implants had initially been associated 
with the onset of the disease, but successive large-scale 
epidemiological studies have not confirmed this initial observation. 
Radiant treatment for neoplasia has been associated both with the 
exacerbation of pulmonary fibrosis in sclerodermic patients, and with 
the onset de novo of the disease [7]. 
 
1.6. SCLERODERMIC VASCULAR DAMAGE 
Vascular damage is considered the primary event in the pathogenesis 
of SSc [21]. It is a systemic process which involves the small blood 
vessels, in particular the arterioles. It precedes fibrosis [22,23] and can 
potentially affect any organ [24,25].  
Endothelial cells are the first cells to be involved in sclerodermic 
damage. Alterations of endothelial cells lead to: increased expression 
of adhesion molecules, recruitment and activation of leucocytes, 
thickening of the basal lamina, proliferation of pericytes, fibroblasts 
and smooth muscle cells, platelet adhesion and activation, and 
formation of perivascular infiltrate. Perivascular infiltrate is 
represented in the first phases by myeloid dendritic cells, by CD4+ T 
lymphocytes and by mastocytes, and in successive phases by 
polymorphonucleates, B and T lymphocytes [26-31]. Growth factors, 
oxidative stress and cytokines stimulate transdifferentiation of the 
fibroblasts into myofibroblasts within the vessel wall, with consequent 
thickening of the vessel wall itself and further reduction of the 
regional blood flow by narrowing the vessel lumen. This is 
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exacerbated by activation of platelets and of the coagulation system, 
with the formation of microthrombi. Unrespective of the progressive 
loss of capillaries and of the high plasma levels of endothelial growth 
factor (VEGF) in response to tissue hypoxia, a deficit in angiogenesis 
is observed [32]. Many consequences of the endothelial damage are 
related to imbalance of vasoactive factors, with hyperproduction of 
endothelin-1 and hypoproduction of nitric oxide and prostacyclin. 
Imbalance of these mediators has an effect not only on vascular tone, 
but also on inflammation, on platelet activation, on myofibroblastic 
induction and on fibrosis, and therefore favouring the perpetuation of 
vasculopathy. 
Chronic perivascular inflammation, in advanced sclerodermic lesion, 
is replaced by fibrosis, which contributes to the permanent alteration 
of the vessel architecture, with thickening of the vessel wall and 
progressive narrowing of the lumen. At cutaneous level, fibrosis 
begins at the deep derma and extends to involve the entire derma and 
the more superficial layers, and a similar course is encountered in the 
other organs affected by the disease. The composition of the 
extracellular matrix varies according to the stage of the disease: 
proteoglycans and elastic fibres such as fibrillin are typical of the first 
phases of the fibrotic process, while type I collagen is found in the 
advanced phases. 
Although the initial manifestations of disease are often limited to 
Raynaud's phenomenon, sclerodermic vascular damage is not limited 
to the skin and at the extremities; indeed the clinical consequences can 
be widespread and associated with organ malfunction and significant 
morbidity and mortality [33]. 
 
  8 
1.7. IMMUNOLOGICAL DYSFUNCTION 
 Immunological alterations are a typical feature of SSc and it still 
unclear whether they are precede or follow vascular damage; it is, 
however, clear that activation of the immune response is an early 
event in the development of the illness. Alterations both of the "first 
line" defences, such as innate immunity, and of the adaptive immune 
system, may induce vascular damage, precipitate autoimmune 
responses, favour the production of autoaggression, and eventually 
lead to tissue fibrosis [34].  
 
1.7.1. INNATE IMMUNITY 
Toll-like Receptors 
In the initial phases of the sclerodermic lesion the perivascular 
infiltrate is mainly represented by myeloid dendritic cells and by 
CD4+ T lymphocytes [26,27]. In the early stages of the disease the 
myeloid dendritic cells of patients with SSc show an increased 
response mediated by Toll Like Receptors (TLR) [35,36]. The TLRs 
are a family of highly conserved receptors, which recognize 
stereotyped non-self molecular patterns, common to numerous 
pathogenic micro-organisms. Among the ligands there are components 
of the bacterial surface, such as lipopolysaccharides (LPS) or 
endotoxin, and RNA and DNA ligands; various ligands can also be 
generated by molecules of the extracellular matrix during tissue 
damage processes [37,38]. TLRs characterize innate immunity cells 
and can be located on the cell surface, like TLR4, or at endosomal 
level, like TLR3. Activation of the TLRs on dendritic cells and on 
monocytes/macrophages stimulates the production of cytokines, 
antigen presentation and trigger the adaptive immune response.  
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In SSc patients the detection of high circulating levels of pro-
inflammatory mediators, such as TNF-α and IL-6, often secreted by 
myeloid dendritic cells after stimulation via TLR [35,39], combined 
with observation of the presence of endogenous agonists for TLR4 in 
the serum [40], supports a role for dendritic cells and TLRs in the 
early stages of the disease. There is also the interesting observation 
that polyinosinic/polycytidylic acid, a TLR3 ligand, is capable in vitro 
to stimulate the production of type I interferon and TGF-β by dermic 
fibroblasts of patients with SSc; also, when injected subcutaneously in 
mice, it is able to induce cutaneous fibrosis [39]. 
Further studies on TLR7, show that its activation can induce 
maturation of autoreactive B lymphocytes [41]. Activation of TLRs 
may also lead to fibrosis, probably via TGF-α [42]. Recent 
observations suggest that activation of TLRs may directly stimulate 
myofibroblastic transdifferentiation through TLR3 [43] and/or TLR9 
[44]. 
 
Interferons 
Patients with SSc show an increased expression of genes responsive to 
interferon (IRGs) [45,46]. Interferons (IFNs) are distinguished into 
Type I IFNs, such as IFN-α and IFN-β; Type II, such as IFN-γ, and 
Type III. Dendritic cells, in particular plasmacytoids (pDCs), are the 
principal source of IFN-α; they produce large amounts of this cytokine 
following activation of TLR7 or TLR9. The serum of patients 
suffering from SSc can stimulate the production of IFN-α by 
peripheral blood mononuclear cells (PBMC) [47]. Fibroblasts are the 
principal producers of IFN-β. Th1 lymphocytes and NK cells are the 
principal producers of IFN-γ. 
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Monocytes/macrophages, IL-4 and IL-13  
Activation of the monocytes/macrophages can occur by means of 
IFN-γ, a cytokine typically produced by the Th1 lymphocytes, or by 
means of IL-4 and IL-13, typically produced by the Th2 lymphocytes.  
IL-4 is capable of favouring the production of collagen by the 
fibroblasts, and increases the production of TGF-β. IL-13 can 
stimulate the monocytes/macrophages to develop a profibrotic 
phenotype, probably by stimulating the production of  TGF-β, and this 
activation may play an important role in fibrosis in patients affected 
by SSc. In line with these findings it has been observed that the 
alveolar macrophages of patients with pulmonary fibrosis produce 
high quantities of IL-13; serum levels of IL-13 are high in patients 
suffering from SSc [48-50]. 
 
1.7.2. ADAPTIVE IMMUNITY 
T Lymphocytes 
SSc is typically considered a predominant Th2 disease [51]. Indeed in 
the serum of SSc patients a preferential production of cytokines 
derived from Th2 lymphocytes, such as IL-4, IL-13, IL-6 and IL-10 
has been observed. IL-4 and IL-13 are among the principal fibrogenic 
cytokines in SSc; they are also able to promote the production of 
antibodies. High levels of IL-17, produced by Th17 lymphocytes have 
also been observed in the serum and the derma of patients with SSc. 
This cytokine favours the proliferation of fibroblasts and stimulates 
the macrophages to produce TNF-α and IL-1, which in turn stimulate 
the fibroblasts to produce collagen.  IL-17 also stimulates endothelial 
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cells to produce IL-1 and IL-6, and to express the adhesion molecules 
ICAM-1 and VCAM-1. 
Although Th2 cells play a crucial role in fibrogenesis and in inducing 
the humoral response, it seems that Th1 cells producing IFN-γ play an 
important role in SSc. Indeed, an increased percentage of IFN-γ 
positive cells among the circulating T cells is observed in the 
peripheral blood of patients. It is therefore possible that Th1 cytokines 
such as TNF-α and IL-1 are involved in the pathogenesis of SSc, 
particularly in the very early stages of the disease. The Th2 cells are 
principally activated by the B lymphocytes producing IL-6 and IL-10, 
while the Th1 cells are principally activated by the dendritic cells 
producing IL-12. CD4+ cells represent the majority of the T 
lymphocytes infiltrating the sclerodermic skin, whereas CD8+ cells 
represent the majority of the T cells infiltrating the pulmonary 
interstitium and are responsible for alveolitis. Both CD4+ T cells in 
the skin and CD8+ T cells in the lung are responsible for the fibrotic 
process. The expansion of T cells in infiltrated tissues seems to be 
oligoclonal, suggesting an antigen driven T cell response, although the 
putative antigens are in large part unknown [52-54]. 
sclerodermic lesions, while they are not reduced in peripheral blood 
[55]; indeed they are often increased in the serum of patients and their 
levels correlate with the activity and severity of the disease [56], 
probably because defective activity of these cells in SSc [57]. 
 
B lymphocytes 
B cells are activated in SSc. This is suggested by the frequent 
presence of hypergammaglobulinaemia, by the production of 
autoantibodies and by the overexpression of CD19 in the peripheral 
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blood cells. Moreover expansion of naïve B cells and activation of B 
memory cells have been reported in SSc patients; however the number 
of the latter is reduced by apoptosis. It is possible that the continous 
loss of memory B cells leads to increased medullary production of 
naïve B cells, so that B cell homoeostasis is maintained. 
Polymorphisms have been demonstrated in the genes of CD19 and 
CD22 in sclerodermic patients. These are associated with 
hyperexpression of CD19, a molecule implicated in positive selection 
of B cells in their process of development in the bone marrow and the 
lymphoid organs, and with hyperexpression of CD22, a molecule 
involved in negative selection. 
For activation, production of autoantibodies and accumulation in 
sclerodermic lesions, B lymphocytes require interaction with T 
lymphocytes. This cross-talk, crucial in the pathogenesis of SSc, is 
carried out by B cells presenting the antigen to CD4+ lymphocytes 
through MHC class II molecules and also by B lymphocytes secreting 
cytokines such as IL-6, IL-10 and TGF-β. 
The activated B lymphocytes contribute to the fibrosis: indeed IL-6 
and IL-10 promote a predominant Th2 immune response, which 
favours collagen synthesis. In addition, IL-6 as well as TGF-β 
production by activated B cells, directly induces fibrosis [53,54,58]. 
 
Autoantibodies 
SSc is characterized by the production of various autoantibodies, some 
of which are important diagnostic markers. 
 Usually autoantibodies directed against intracellular antigens are 
correlated with particular clinical subsets: typically, the diffuse form is 
associated with the presence of anti-Scl-70 antibodies, while the 
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limited form is associated with the presence of anti-centromere 
antibodies. The association is also known between particular 
autoantibodies and certain clinical manifestations: the presence of anti 
topoisomerase-1 autoantibodies correlates with an increased risk of 
interstitial lung disease; anti-RNA polymerase-3 autoantibodies 
correlate with a greater probability of developing sclerodermic renal 
crisis, while they are rarely present in patients with severe pulmonary 
involvement [59,60]. Anticentromere and anti-U3 RNP autoantibodies 
are frequently found in the serum of patients with pulmonary 
hypertension [61]. Anti-U3 RNP autoantibodies are also associated 
with sclerodermic cardiopathy. Anti U11/U12 RNP autoantibodies are 
present in sclerodermic patients with pulmonary hypertension and 
they seem to be correlated with the severity of the prognosis [62].  
Although these autoantibodies correlate with the severity of the 
disease and with the risk of developing complications, they are 
commonly believed to have no pathogenetic role. Autoantibodies 
against surface antigens, such as autoantibodies against endothelial 
cells [63], the PGDF receptor [64], the receptor for angiotensin-1 and 
the receptor ETA for ET-1 [65], are thought to have a  pathogenetic 
role in triggering the endothelial cell damage and the fibrotic process. 
Among the anti-endothelial cell autoantibodies, anti-NAG2 antibodies 
are present in large numbers of SSc patients, without differences 
between the limited and diffuse clinical forms. NAG2 is a tetraspanin 
expressed on the surface of the epithelial cell associated with 
integrins. It has a high sequence homology with the HCMV derived 
protein UL94; patients present cross-reactive antibodies which can 
recognize the viral epitope of HCMV and NAG2 through a molecular 
mimicry mechanism. In vitro, it has been demonstrated that anti-
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NAG2 antibodies are able to induce apoptosis of the epithelial cells 
and to promote the proliferation of fibroblasts. These antibodies could 
thus induce the disease by directly favouring two of the basic 
pathogenetic mechanisms of SSc: endothelial damage and fibrosis 
[18] (Figure 1). 
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2. ENDOTHELIN-1 
Endothelin-1 (ET-1) is a key mediator known for its vasoconstrictor 
effect. Various other effects of ET-1 have recently been identified: 
inflammation, cell adhesion, fibrosis and angiogenesis. All these 
aspects are important in the pathogenesis of SSc. For these reasons, 
besides the anti-vasoconstrictor effect, ET-1 receptor antagonists 
(ERAs) represent one of the most promising therapeutic options in 
sclerodermic patients.  
It has been shown that ET-1 and its receptors play an important role in 
the pathogenesis of various diseases, among them: atherosclerosis and 
cardiovascular pathologies, pre-eclampsia, renal pathologies, 
pulmonary pathologies including pulmonary hypertension, 
carcinogenesis and other fibrosing pathologies besides SSc. 
 
2.1. ISOFORMS AND EXPRESSION 
There are four isoforms of endothelin: ET-1, ET-2, ET-3 and ET-4. 
ET-1 was first identified in endothelial cells. It is expressed by a large 
number of cells, among them smooth muscle cells in the vessel wall, 
fibroblasts and myofibroblasts, mastocytes, monocytes/macrophages, 
polymorphonucleates, dendritic cells and many others [66,67]. ET-2 is 
mainly expressed by intestinal and renal cells. ET-3 is found at high 
concentrations in CNS. Little is known about ET-4 (Table I). 
 
2.2. SYNTHESIS 
The gene coding preproET-1 is located on the short arm of 
chromosome 6, distally to locus HLA. Activation of this gene is 
regulated by transcription factors among which c-fos, c-jun, NFkB-1, 
AP-1 and GATA-2. Early transcription codes for preproET-1 which, 
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following post-transcriptional modifications, is first converted to pre-
ET-1 and then to big-ET-1. The latter, which is also present in the 
extracellular compartment and in the serum, is then converted to ET-1 
by dedicated enzymes (Figure 2).  
Production of ET-1 is stimulated by hypoxia, by exposure to cold, by 
low wall tension, by angiotensin II, by growth factors and by cytokine 
including TGF-β [66,67]. Its production is inhibited by nitric oxide 
(NO), by prostacyclin, by natriuretic peptide, by increase in blood 
flow and by increase in wall tension [68].  
 
2.3. ENDOTHELIN CONVERTING ENZYME AND MATRIX 
METALLOPROTEASE-1 
Endothelin converting enzyme (ECE) and matrix metalloprotease-1 
(MMP-1) have opposite effects on the metabolism of endothelin: the 
first is the principal activator, the latter is its principal inactivator.  
ECE is a protease, bound to the plasma membrane or the Golgi 
network membrane, which cleaves BigET-1 into the biologically 
active form: ET-1 [66,69]. Three isoforms of ECE are known. ECE-1, 
comprising the isoforms ECE-1a, ECE-1b, ECE-1c, ECE-1d, 
performs its function optimally if the pH is around 7 and is expressed 
preferentially by the smooth muscle cells. Its function is not only to 
hydrolize Big-ET, but also to hydrolize other molecules such as 
bradykinin, substance P and insulin. It has a greater specificity for ET-
1.  
ECE-2 is expressed in the membranes of the Golgi network. It is 
found in large quantities in the cells of nervous system and in the 
endothelial cells, and works optimally at a pH of 5. It has greater 
specificity for ET-1. Little is known about the ECE-3. 
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MMP-1 cleaves mature ET-1, making the peptide biologically inactive 
[70,71]. 
 
2.4. SECRETION 
Secretion of ET-1 occurs by means of granules after stimulus and 
constitutively as a basal secretion [65]. In the first case the mechanism 
is regulated and secretion occurs only through specific stimuli: 
hypothermia, mechanical stress, or through the action of histamine 
and thrombin. Basal secretion on the other hand is carried out 
principally by the basolateral portions of the endothelial cell as a 
continuous secretion; however, it can be affected by vasodilatation 
and by the release of NO. 
  
  18 
3. RECETTORI DELL’ET-1ET-1 
RECEPTORS 
 
3.1. ISOFORMS 
Three receptor isoforms are known: ETA, ETB and ETC.  
ETA binds both ET-1 and ET-2 with high avidity and ET-3 with low 
avidity; it is more specific for ET-1. ETB binds ET-1, ET-2 and ET-3 
with the same specificity. Little is known about the role of ETC.  
Endothelin receptors are expressed on various cell types. The effects 
depend, besides the type of receptor bound and the cell type 
stimulated, also on the tissue conditions. Indeed both the number and 
the avidity of the receptors can be different in pathological conditions, 
such as during an inflammatory process [65,71]. 
 
3.2. EARLY AND LATE RESPONSES TO ET-1. 
Early responses mediated by the endothelin receptors occur within a 
few minutes and are transient. They principally promote cellular 
contraction.  
Late responses are slower and take hours or days to be evident. They 
consist of transcriptional activation of genes important for regulating 
the cell matrix, strengthening the contractile function of the smooth 
muscle cells, and altering the tissue composition [72]. 
 
3.3. EXPRESSION AND ROLE OF ETA AND ETB 
There is evidence that the majority of cells potentially involved in the 
pathogenesis of SSc, among them endothelial cells, smooth muscle 
cells, fibroblasts and myofibroblasts, monocytes/macrophages, 
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polymorphonucleates, mastocytes, platelets and dendritic cells express 
the receptors for ET-1 [65,66,69,71]. These have also been observed 
on myocardiocytes. ET-1 also plays an important role in cardiac 
remodelling (Table II).  
 
3.4. ET-1 RECEPTORS IN ENDOTHELIAL CELLS AND 
SMOOTH MUSCLE CELLS OF THE VESSEL WALL 
Endothelial cells express exclusively ETB, while smooth muscle cells 
express both ETA and ETB. 
ET-1 binds ETB on endothelial cells and stimulates the production of 
NO, a potent vasodilator, by eNOS activation. In physiological 
conditions the vascular smooth muscle cells receive stimuli both from 
NO and from ET-1, in such a way that there is a balance between 
relaxation and contraction of the myofibrils (Figure 3).   
ET-1, binding ETA on smooth muscle cells, induces both signal 
transduction mechanisms capable of promoting contraction and 
pathways which induce hypertrophy and hyperplasia [73,74] (Figure 
4).  
 
3.5. ET-1 RECEPTORS ON FIBROBLASTS 
Fibroblasts are cells capable of producing large quantities of collagen. 
Various profibrotic stimuli converge on them; among these an 
important role is played by ET-1 and TGF-β, besides the Th2 
cytokines and IL-17. 
The fibroblasts express both ETA and ETB and are capable of 
producing ET-1. Some studies suggest that ET-1 can activate the 
production of collagen and induce the expression of ICAM-1 on the 
surface of fibroblasts. It may also stimulate the fibroblasts themselves 
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to transdifferentiate into myofibroblasts [75,76] and to reprogram the 
functional phenotype of the smooth muscle cells and of the 
microcirculation pericytes into a pro-fibrogenic cell population with 
myofibroblastic properties [77]. Furthermore, it has been observed 
that the production of collagen by fibroblasts induced by ET-1 is not 
reduced by the selective antagonism of ETA or ETB, while it is 
reduced by combined ETA/ETB antagonism. This would suggest the 
existence of cross-talk between the two receptors inducing signal 
transduction pathways that lead to the production of collagen. 
Moreover, the combined ETA/ETB antagonism reverts the phenotype 
of the fibrotic fibroblasts to that of normal fibroblasts [76,78]. 
Conversely, the selective ETA blockage does not reduce the 
production of collagen whereas it reduces the expression of β-SMA 
and the contraction of the extracellular matrix [77].  
Various mechanisms have been proposed for the signal transduction 
pathways involved in the induction of tissue fibrosis stimulated by 
ET-1 [76,79]. These would imply cross-talk between the ETA and ETB 
receptors, which are associated with protein Gq/12/13, with the 
activation of signal transduction pathways which would stimulate the 
expression of α-SMA, cellular contraction and the production of 
collagen [77]. 
The importance of ET-1 in the genesis of fibrosis is strengthened by 
evidence of the existence of autocrine loops producing ET-1 and of 
induction of fibrosis by the fibroblasts. The latter in fact can both 
express the receptors ETA and ETB and produce ET-1. TGF-β may 
function as a trigger for establishing these loops which could 
potentially be self-maintaining. TGF-β and ET-1 would therefore 
work in concert in the pathogenesis of fibrosis in SSc. In fibroblasts, 
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TGF-β stimulates the production of collagen through a classic 
transduction pathway depending on ALK5/Smad; induction of the 
production of ET-1 may occur through a pathway dependent on 
ALK5/JNK/Ap-1 [80,81].  
It is interesting to note that fibrosis in SSc is accompanied by 
imbalance in the ratio between ETA and ETB in favour of ETB in the 
fibroblasts [75,82] and alteration of the equilibrium between 
metalloproteases (MMPs) and tissue inhibitors of metalloprotease 
(TIMP), with an increase in many MMPs, in particular MMP-2, which 
can convert the inactive precursors of ET-1 into active ET-1 [83]. 
 
3.6. ET-1 RECEPTORS IN THE MONOCYTES/MACROPHAGES 
ET-1 is among the first mediators to be produced in the inflammatory 
cascade [84].  
The monocytes/macrophages can both produce ET-1 and express 
receptors ETA [85] and ETB [86]; this can trigger an autocrine loop and 
hyperstimulate the production of pro-inflammatory cytokines. 
Some observations suggest that ET-1 is responsible for the 
amplification of the inflammatory cascade in monocytes/macrophages 
[87-89], activating the transcription of specific mRNAs, through a 
signal transduction pathway triggered by ETB. 
In particular, in the monocytes/macrophages, the stimulation of ETB 
by ET-1 induces an increase in the production of pro-inflammatory 
molecules, such as TNF, PGE2, IL-1β; a larger production of free 
radicals of oxygen through activation of iNOS; and the regulation of 
the mechanisms of cell adhesion and recruitment. In vitro it has been 
observed that the receptor antagonist ETA/ETB (Bosentan) may 
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attenuate the response of the human monocytes/macrophages to ET-1 
[86]. 
 
3.7. ET-1 RECEPTORS IN THE POLYMORPHONUCLEATES 
 Polymorphonucleates (PMNs) express both ETA [85] and ETB [90]. 
A recent study has shown that the platelets and neutrophils can 
synthesize 20-hydroxyeicosatetraenoic acid (20-HETE), a metabolite 
of arachidonic acid important in the regulation of vascular tone and in 
the control of renal function and arterial pressure, in response to 
angiotensin II and ET-1. In both cell types the synthesis of 20-HETE 
may be induced mainly through the binding of the ligands to the 
respective receptors AT2 and ETB [90]. 
 
3.8. ET-1 RECEPTORS IN THE DENDRITIC CELLS 
The dendritic cells (DCs) produce large quantities of ET-1 and 
significantly increase the expression of ETA and ETB after maturation. 
ETA is important for the maturation of the DCs, the production of IL-
12, the stimulation of the T lymphocytes and for inhibiting the 
apoptosis of the DCs. ETB, on the other hand, is however, important 
for inhibiting maturation and inducing apoptosis of the DCs [91]. 
 
3.9. ET-1 RECEPTORS AND AUTOANTIBODIES 
Riemekasten et al. have recently demonstrated the presence of 
autoantibodies against ETA in the majority of patients with SSc. Their 
presence may be associated with more serious clinical manifestations, 
with higher mortality and an increased expression of TGF-β by the 
endothelial cells. According to these authors, anti-ETA autoantibodies 
bind the receptor expressed on the endothelial cells [92]. It is not clear 
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why these antibodies have been found only in endothelial cells since 
these cells exclusively express the receptor ETB. 
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4. ENDOTHELIN-1 AND 
TREATMENT 
 Although a considerable progress has been made in the last few 
decades, at the moment there is no treatment able to significantly 
modify the natural history of the disease. The choice of each 
therapeutic regimen is a challenge both because of the heterogeneity 
of the clinical manifestations, because of their progression and their 
severity, and because the pathogenesis of SSc is not yet altogether 
understood. 
Corticosteroids at low dosages are useful for controlling the 
inflammatory symptoms, such as oedema in the early phases of 
cutaneous involvement, myositis, serositis, arthritis and tenosynovitis. 
Long-term treatment with these drugs should be avoided, also because 
they can precipitate a sclerodermic renal crisis. 
The therapeutic choices must be individually tailored, and for this 
reason it is necessary to carry out an accurate staging of the disease, 
before starting any “DMARDs” treatment, and follow its course over 
time. The available “DMARDs” drugs act principally on the vascular 
damage and on the alterations to the immune system with no or little 
effects on the fibrotic process [7]. 
 
4.1. ANTAGONIST DRUGS TO ET-1 RECEPTORS 
The introduction of ET-1 receptor antagonist drugs has improved the 
management and prognosis of patients with recurrent digital ulcers 
and with pulmonary hypertension associated with SSc. Clinical 
studies have provided encouraging results even on cutaneous fibrosis 
and on Raynaud's phenomenon. Furthermore recent observations 
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about the anti-inflammatory effects of ERAs make these drugs 
promising for the future as disease modifying drugs. 
Since ET-1 is a mediator implicated in various pathogenetic aspects of 
SSc, including vasoconstriction, mitogenesis and hypertrophy of the 
vascular smooth muscle cells, collagen deposition and myofibroblastic 
induction, its use in affected patients is reasonable. ET-1 levels are 
also increased in plasma, derma and internal organs of patients with 
SSc. In particular ET-1 levels are high in the broncoalveolar washing 
liquid of patients with SSc and pulmonary involvement, including 
those with pulmonary arterial hypertension, in which ET-1 levels 
correlate with the severity and the prognosis of this complication [93-
95]. 
Among the disadvantages of ERAs are the slow clinical response, 
generally 3-6 months from the beginning of treatment, the cost and the 
adverse effects. The principal one of these, common to all of them, is 
an increase in hepatic transaminases, which may or may not be 
associated with gastrointestinal symptoms. For Bosentan this effect is 
usually moderate and transitory, occurring in about 10% of cases. It is 
therefore advisable to monitor the hepatic cytolysis enzymes before 
starting treatment, every 15 days for a month and then monthly after 
the beginning of treatment. If an increase in transaminases occurs it is 
necessary to reduce dosage of the drug or suspend it. Full blood count 
must be checked as well as renal function. Moreover the possible 
interaction with other drugs must be considered: Bosentan is both a 
substrate and an inducer of the cytochromes CYP2C9 and CYP3A4 
and can therefore reinforce their activity, thus altering the metabolism 
of numerous other drugs commonly used; among them oral 
anticoagulants, statins, oral hypoglycaemiants, tricyclic 
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antidepressants,  benzodiazepines and some antibiotics. Oedema at the 
extremities appears frequently [96]. Ambrisentan, a selective ETA 
inhibitor, has a toxicity profile similar to that of Bosentan [97]. 
 
Bosentan. 
Bosentan is a sulfonamide derivative for oral administration with 
affinity for the receptors ETA and ETB. The usual dosage is 65 mg 
twice a day for the first four weeks and, if well tolerated, 125 mg 
twice a day. 
It was the first ERA approved in Europe and the USA (from 2002) for 
the treatment of pulmonary hypertension associated with SSc, in 
patients with WHO functional class grade III, i.e. those patients with 
marked limitation of their physical activities. Bosentan has 
demonstrated significant efficacy in reducing the mean pressure in 
pulmonary artery (mPAP), in improving the tolerance to exercise and 
in delaying the progression of the pulmonary arterial hypertension 
(PAH) not only in patients in WHO grade III but also in asymptomatic 
patients. It is also capable of reversing the process of cardiac 
remodelling and improving right ventricular function and cardiac 
output [98-100]. 
Bosentan is also approved for treating recurring ischaemic digital 
ulcers in patients with SSc.  It reduces the incidence of new ulcers, 
pain and disability but has no effect on recovery from ulcers already 
present [101,102]. 
Clinical studies have shown that treatment with Bosentan in patients 
with SSc and severe Raynaud's phenomenon significantly improves 
the frequency, duration and severity of painful attacks, especially in 
patients with previous ischaemic digital ulcers. In patients without this 
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complication, however, it improves functional disability [103-105]. It 
has been observed that the degree of cutaneous fibrosis improves 
significantly in treated patients especially those with dSSc [106]. 
The observations on the anti-inflammatory effects of Bosentan used in 
vitro and in vivo are also interesting. In vitro Bosentan amplifies the 
inflammatory cascade, stimulating the production of TNF and other 
mediators by monocytes/macrophages [86]. In vivo, after 12 months 
of treatment we observe the normalization of the concentration of 
soluble adhesion proteins in patients' serum [107]. Furthermore, in 
patients with PAH and SSc, there is a significant reduction in the 
serum levels of IL-6, ICAM-1 and BNP, accompanying 
haemodynamic and clinical improvement [108]. 
In the vascular smooth muscle cells, the predominant effect is the 
blocking of ETA, responsible for the pathological modifications of the 
vessel wall. It is therefore hypothezised that Bosentan opposes the 
vasoconstrictive and proliferative effect induced by ET-1 by blocking 
the ETA and it induces an anti-inflammatory and anti-fibrotic effect by 
blocking the ETB. In the fibroblasts, moreover, the production of 
collagen induced by ET-1 is not reduced by the selective antagonism 
of ETA or ETB, while it is reduced by combined ETA/ETB antagonism.  
 
Ambrisentan 
Ambrisentan is a non-sulfonamide ERA, selective for ETA (260:1 ETA 
vs ETB), approved in the USA in 2007 and subsequently in Europe for 
the treatment of PAH associated with SSc. Like Bosentan, 
Ambrisentan too has demonstrated beneficent effects in patients in the 
early stage of the disease, and is indicated in patients with PAH of 
WHO I, II and III. The usual dosage is 5-10 mg once a day. The drug 
improves haemodynamic parameters, tolerance to exercise and WHO 
grade and retards the clinical worsening of the patients treated [109]. 
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5. AIM OF THE WORK 
 
ET-1 plays a pivotal role in vasoconstriction, fibrosis and 
inflammation, the three major aspects in the pathogenesis of SSc. The 
ET-1 receptors are ETA and ETB. The receptors are expressed on the 
majority of cells involved in SSc, such as endothelial cells, smooth 
muscle cells and fibroblasts. Little is known about the expression of 
ET-1 receptors on leukocytes, except for macrophages and 
monocytes; there is no information about the expression of ETA and 
ETB on lymphocytes, neutrophils or other cells involved in the innate 
and acquired immune response. Endothelin receptor antagonists are 
used in the treatment of scleroderma patients with recurrent ischemic 
digital ulcers and/or pulmonary arterial hypertension. They have 
beneficial effects on vasoconstriction and fibrosis, but less is known 
about their anti-inflammatory role. 
We aimed at studying the link between ET-1 and inflammation in SSc. 
Since T and B cells, monocytes and neutrophils are among the most 
important cells in inflammatory responses in SSc, we studied ETA and 
ETB expression on these cells with flow cytometry, and also ETA- and 
ETB-coding mRNA expression in CD4+ T cells and neutrophils  using 
RT-PCR. In studying T and B cells, we observed the differences in 
receptor expression between patients and controls, and we made 
correlations with the cutaneous form of the disease, pulmonary arterial 
hypertension, interstitial lung disease, Bosentan therapy, and ischemic 
digital ulcers in SSc patients. We also studied the modulation of 
receptors on activated T cells with flow cytometry, and how ET-1 
influences the production of some cytokines such as IFN-γ, IL-4, IL-6, 
IL-10 and IL-17 in CD4+ T cells, by ELISA and RT-PCR in different 
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condition (with and without blocking ETA and ETB ) and time points, 
in order to understand the timing of CD4+ T cells response to 
stimulation with ET-1, its hypothesized proinflammatory effects and 
the anti-inflammatory effects of Bosentan. Finally we studied the 
response of neutrophils to ET-1 stimulus by evaluating, with ELISA, 
the production of IL-8, MMP9, TNF-α, VEGF, IFN-γ and IL-17. 
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6. MATERIALS AND METHOD 
 
Patients and controls 
We enrolled 41 SSc patients (mean age 56.4±13.5 years; 5 male and 
36 female) attending the Unit of Autoimmune Diseases of this 
University Hospital, and 22 healthy controls, sex and age matched. 
All patients fulfilled the ACR criteria for the diagnosis of SSc [35]. 
The distinction between limited and diffuse cutaneous SSc was made 
according to the criteria of Le Roy at al. [36]. Of these patients, 32 
was affected by lSSc and 9 by dSSc. 
Ischaemic DUs were defined as necrotic areas located at distal digits 
with loss of both epidermis and dermis; whereas scleroderma 
contracture ulcers were defined as ulcers overlying bony prominence 
at the site of joint contractions. Skin fissures and areas of calcium 
extrusion were not included. 
All the patients underwent examination and laboratory evaluation 
comprehensive of detection of antibodies to antinuclear proteins and 
anti-extractable nuclear antigens, respectively by indirect 
immunofluorescence on Hep-2 cells and the enzyme-linked 
immunosorbent assay method. 
All patients underwent the following instrumental investigations: 
chest radiograph, pulmonary function test with diffusing capacity for 
carbon monoxide adjusted to haemoglobin, Doppler echocardiogram 
to estimate pulmonary artery systolic pressure (sPAP). If no tricuspid 
regurgitation could be detected, sPAP was presumed normal, and if 
estimated sPAP was >35 mmHg it was considered abnormal. 
Pulmonary fibrosis was detected by X-Ray and High Resolution 
Computed Tomography (HRCT) of the chest, and it was considered 
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pathological only if there were ground glass or honeycombing areas in 
the lung. 
We also collected information about patients' treatment, particularly 
with Bosentan. 
Blood samples (20 ml) were collected from patients and controls in 
heparinized Falcon tubes (Becton Dickinson, NJ, USA). 
 
Isolation of peripheral blood mononuclear cells and flow-cytometry 
Peripheral blood mononuclear cells (PBMC) were isolated through 
density gradient centrifugation using Lymphoprep Ficoll-Isopaque 
(Axis-Shield, Oslo, Norway), and separated in tubes, each containing 
1 million cells. 
Monocyte-dedicated tubes were pre-incubated for 10 minutes at room 
temperature with mouse serum (DAKO, Glostrup, Denmark). We then 
used the following antibodies: rabbit polyclonal anti-ETA (Acris 
Antibodies GmbH, Herford, Germany), sheep polyclonal anti-ETB 
(Lifespan Biosciences, Seattle, WA, USA), phycoeritrin (PE)-
conjugated goat anti-rabbit IgG monoclonal secondary for ETA (R&D 
Systems, Minneapolis, MN, USA), PE-conjugated donkey anti-sheep 
IgG monoclonal secondary for ETB (R&D Systems). We incubated 
PBMC for 1 hour at 4°C with anti-ETA (0.25 mg/ml) and anti-ETB 
(0.2 mg/ml) antibodies, and for 30 minutes at 4°C with PE-conjugated 
secondary antibodies. Samples were also stained for 20 minutes at 
room temperature in a dark room with allophycocyanin (APC)-
conjugated anti-CD3 and anti-CD14 antibodies (BD Biosciences, San 
Jose, CA, USA). 
Resuspended samples were analysed on a FACSCalibur cytometer 
(BD Biosciences): 20,000 CD3+ or CD14+ cells per sample were 
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acquired in live gating. CellQuest software (BD Biosciences) was 
used to analyse data. Median florescence intensity (MFI) was 
determined for each sample. MFI was calculated for samples 
incubated with both primary anti-receptor and PE-conjugated 
secondary antibodies (receptor MFI) and for samples incubated only 
with PE-conjugated secondary antibody (IgG MFI). ETA and ETB 
expression on T cells and monocytes was then assessed by the 
following equation: ∆MFI= receptor MFI - IgG MFI. We also 
determined the ETA/ETB ratio (∆MFI of ETA/∆MFI of ETB). 
 
T cell stimulation 
In order to assess receptor expression on activated CD4+ and CD8+ T 
cells, PBMCs were obtained from 4 patients and 4 sex- and age-
matched healthy controls and stimulated for 24 hours with anti-
CD3/CD28 antibody coated microbeads: Dynabeads Human T-
Activator (Dynal, Oslo, Norway). Cells were stimulated according to 
the manufacturer’s recommendations. In order to distinguish T cells 
from other cells and CD4+ from CD8+ cells, we used the following 
antibodies: peridinin chlorophyll protein (PerCp)-conjugated anti-
CD3, APC-H7-conjugated anti-CD4, APC-conjugated anti-CD8. 
Activated cells were detected by incubating cells with fluorescein 
(FITC)-conjugated anti-CD25 antibodies. All reagents were purchased 
from BD Biosciences. Cells were also stained with anti-ETA, anti-
ETB and secondary antibodies. Incubations were performed as 
described above. 
Samples were analysed on a FACSCanto cytometer (BD Biosciences). 
FlowJo software (Treestar, Ashland, OR, USA) was used to analyse 
data. The receptor expression variation was expressed as difference 
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between the MFI of activated cells and the MFI of unactivated cells 
MFI (∆∆MFI). 
 
Isolation of CD4+ T cells 
We isolated CD4+ T cells from healthy donor buffy coat. Isolation of 
CD4+ T cells was a preliminary to studying the expression of ETA- 
and ETB-coding mRNA (with RT-PCR). Isolation was obtained 
through negative selection using CD4+ T Cell Isolation Kit II 
(Miltenyi Biotec, Cologne, Germany) and MidiMACS Starting Kit, 
including MACS LD column and MACS Separator (Miltenyi Biotec), 
following manufacturer’s instructions. 
 
Isolation of RNA and RT-PCR from CD4+ T cells 
Total RNA was extracted from CD4+ T cells using TRIzol Reagent 
(Gibco BRL, Billings, MT, USA) according to the manufacturer’s 
protocol. 
In order to verify the production of ETA- and ETB-coding mRNA by 
CD4+ T cells, we generated first-strand cDNA using the Super Script 
III System (Invitrogen, Carlsbad, CA, USA), with random hexamers, 
according to the manufacturer’s recommendations. RNA was 
previously treated with DNAse I (Invitrogen). Fibroblast cDNA was 
used as a positive control for the expression of ETA- and ETB-coding 
mRNA. CD4+ T and fibroblasts cDNA coding to ETA- and ETB- was 
amplified with sequence-specific primers: ETA forward 5’-
ATGCACAACTATTGCCCACA-3’, ETA reverse 5’-
GGACAGGATCCAGATGGAGA-3’, ETB forward 5’-
GCACATCGTCATTGACATCC-3’, ETB reverse 5’-
CAGAGGGCAAAGACAAGGAC-3’ (Sigma-Aldrich, Saint Louis, 
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MO, USA). Sequence-specific primers were used to amplify cDNA 
coding vimentin (housekeeping gene), as a PCR reaction control. 
Amplification was performed using the AmpliTaq Gold PCR 
MasterMix system (Applied Biosystems, Foster City, CA, USA), 
following the manufacturer’s instructions. Reaction components were 
mixed and PCR tubes dedicated to the production of ETA-, ETB- and 
vimentin-coding amplicons were prepared. Thermic cycles with the 
GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) 
were performed as follows: 10 minutes at 95°C to start reaction, 60 
cycles of denaturation (45 seconds at 94°C), annealing (30 seconds at 
53°C for ETA, at 55°C for ETB, at 53°C or 55°C for vimentin) and 
extension (1 minute at 72°C), and 7 minutes at 72°C to stop reaction. 
Amplicons (length: 447 bp for ETA, 558 bp for ETB, 266 bp for 
vimentin) were separated on agarose gel (1.5%). VersaDoc video 
documentation system (Bio Rad, Hercules, CA, USA) was used to 
document the electrophoretic separation. 
 
Study of cytokine response to ETA- and ETB-stimulation by ET-1 in 
CD4+ T cells 
In order to study cytokine response to ETA- and ETB-stimulation by 
ET-1 in CD4+ T cells, we distributed the CD4+ isolated cells in 
microplates and we incubated the cells at first with selective 
antagonists for ETA and ETB; we then added the stimulus with ET-1. 
We studied the cytokine response with ELISA at different times (3, 6 
and 24 hours) in order to quantify IFN-γ and IL-4 production in 
microplate supernatants and the timing of the response of the CD4+ T 
cells to stimulation with ET-1. 
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Receptor blockage/stimulation test 
CD4+ T cells were distributed in 5 plates. We incubated cells with 
neither ETA (BQ123)- nor ETB (BQ788)-antagonists nor stimulus (ET-
1) in one plate (basal cells). We made the following incubations in the 
other plates: ET-1; BQ123 and ET-1; BQ788 and ET-1; BQ123, 
BQ788 and ET-1. BQ123 and BQ788 at the concentration of 10-6 M 
were incubated for 45 minutes, ET-1 at the concentration of 10-7 M 
was incubated for 24 hours. In plates in which we incubated both the 
antagonists and ET-1, the antagonists were incubated first. All 
reagents were purchased from Sigma Aldrich. 
 
RT-PCR and evaluation of IFN-γ-, IL-4-, IL-6-, IL-10- and IL-17-
coding mRNA in response to ET-1 stimulus 
Total RNA was extracted from CD4+ T cells using TRIzol Reagent 
(Gibco BRL, Billings, MT, USA) according to the manufacturer’s 
protocol. 
In order to verify the production of IFNγ-, IL-4-, IL-6-, IL-10- and IL-
17-coding mRNA by CD4+ T cells, we used sequence-specific 
TaqMan probes marked with the fluorophore 6-carboxy-fluorescein 
(FAM) and that have as quencher dihydrochloro-pyrrole (MGB).  
The PCR reactions were prepared in 96-well plates by mixing 12.5 µl 
of TaqMan MasterMix (Applied Biosystems) containing Taq Gold 
polymerase, uracilDNA glycosylase, deoxyribonucleotides (dATP, 
dGTP, dCTP, dTTP and dUTP) and buffer, 1.25 µl of TaqMan assay, 
2 µl of cDNA and 9.25 µl of water (total volume 25 µl). In 
thermocycler Sequence Detection System 7300 (Applied Biosystems), 
the samples were subjected to a thermal cycle which consisted of 2 
minutes at 50° C, to allow the activation of uracilDNA glycosylase, 10 
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minutes at 95° C to allow the activation of Taq Gold polymerase and a 
subsequent 40 cycles of denaturation (15 seconds at 95°C) and 
annealing/extension (1 minute at 60°C). The amplification of the 
cDNA was quantified by evaluating the increase of fluorescence 
during the exponential phase of the PCR reaction, using the software 
Sequence Detector System (Applied Biosystems). We obtained the 
∆CT for each condition by subtracting the CT (threshold cycle) of the 
endogenous control 18s (a constitutively expressed housekeeping 
gene) from the CT of the transcript that we considered. We then 
calculated ∆∆CT by subtracting the ∆CT of the basal condition from 
the ∆CT of non-basal conditions. We thus obtained a fold change (FC) 
for each condition using the equation: FC = 2-ΔΔCt. 
 
Evaluation of cytokine response by ELISA 
The supernatant concentrations of IFN-γ and IL-4 were measured by 
enzyme-linked immunosorbent assay (ELISA). IFN-γ kit and IL-4 kit 
(Quantikine Human IFN-γ Immunoassay and Quantikine Human IL-4 
Immunoassay respectively) were purchased from R&D Systems. 
Samples containing supernatants at appropriate dilutions were 
prepared and the assay was performed following the manufacturer’s 
recommendations. Sunrise absorbance reader for microplates (Tecan, 
Salzburg, Austria) was used to determine optical density for each 
sample. 
 
Isolation of neutrophils and RT-PCR 
We isolated neutrophils from healthy donor buffy coat in order to  
study ETA and ETB expression on the cell surface by flow cytometry 
and the expression of ETA- and ETB-coding mRNA by RT-PCR. 
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Highly purified granulocytes (neutrophils > 96.5%) were isolated and 
prepared under endotoxin-free conditions using Lymphoprep Ficoll-
Isopaque (Axis-Shield, Oslo, Norway). Ficoll-Paque–isolated 
neutrophils were further enriched by positively removing all 
contaminating cells with mAb against CD3, CD56, CD19, CD36, 
CD49d, and Gly-A using a custom-made EasySep® kit (StemCell 
Technologies, Vancouver, BC, Canada), to reach > 99.7% purity (high 
purity neutrophils).  
Total RNA was extracted from neutrophils using TRIzol Reagent 
(Gibco BRL, Billings, MT, USA) according to the manufacturer’s 
protocol. 
In order to verify the production of ETA- and ETB-coding mRNA by 
neutrophils, we generated first-strand cDNA using the Super Script III 
System (Invitrogen, Carlsbad, CA, USA), with random hexamers, 
according to the manufacturer’s recommendations. RNA was 
previously treated with DNAse I (Invitrogen). Fibroblast cDNA was 
used as a positive control for the expression of ETA- and ETB-coding 
mRNA. Neutrophils and fibroblasts cDNA coding to ETA- and ETB- 
was amplified with sequence-specific primers: ETA forward 5’-
ATGCACAACTATTGCCCACA-3’, ETA reverse 5’-
GGACAGGATCCAGATGGAGA-3’, ETB forward 5’-
GCACATCGTCATTGACATCC-3’, ETB reverse 5’-
CAGAGGGCAAAGACAAGGAC-3’ (Sigma-Aldrich, Saint Louis, 
MO, USA). Sequence-specific primers were used to amplify cDNA 
coding vimentin (housekeeping gene), as a PCR reaction control. 
Amplification was performed using the AmpliTaq Gold PCR 
MasterMix system (Applied Biosystems, Foster City, CA, USA), 
following the manufacturer’s instructions. Reaction components were 
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mixed and PCR tubes dedicated to the production of ETA-, ETB- and 
vimentin-coding amplicons were prepared. Thermic cycles with the 
GeneAmp PCR System 9700 thermal cycler (Applied Biosystems) 
were performed as follows: 10 minutes at 95°C to start reaction, 45 
cycles of denaturation (1 minute at 95°C), annealing (1 minute at 50°C 
for ETA, at 58°C for ETB, at 72°C for vimentin) and extension (1 
minute at 72°C), and 10 minutes at 72°C to stop reaction. Amplicons 
(length: 447 bp for ETA, 558 bp for ETB, 266 bp for vimentin) were 
separated on agarose gel (1.5%). VersaDoc video documentation 
system (Bio Rad, Hercules, CA, USA) was used to document the 
electrophoretic separation. 
 
Study of the cytokine response after stimulation by ET-1 in neutrophils 
In order to study the cytokine response after stimulation by ET-1, we 
distributed the isolated neutrophils in microplates and incubated with 
or without 100 ng/mL Ultrapure E. coli LPS (Invivogen, San Diego, 
CA) and with or without ET-1. In this way we considered 4 
conditions: neutrophils without stimulus as negative control, 
neutrophils with ET-1 or LPS alone and with both ET-1 and LPS. We 
studied the cytokine response with ELISA at different times (3 and 10 
hours) in order to quantify IL-8, MMP9, TNF-α, VEGF, IFN-γ and 
IL-17 production in microplate supernatants and the timing of 
neutrophils response to ET-1 stimulus. 
 
Evaluation of cytokine response by ELISA 
The supernatant concentrations of IL-8, MMP9, TNF-α, VEGF, IFN-γ 
and IL-17 were measured by enzyme-linked immunosorbent assay 
(ELISA). Quantikine Human Immunoassay for these specific 
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cytokines was purchased from R&D Systems. Samples containing 
supernatants at appropriate dilutions were prepared and the assay was 
performed following the manufacturer’s recommendations. Sunrise 
absorbance reader for microplates (Tecan, Salzburg, Austria) was used 
to determine optical density for each sample. 
 
Statistical analysis 
All the calculations were performed with SPSS 18.0 statistical 
package (SPSS Inc., Chicago, IL, USA). All results are expressed as 
mean ∆MFI ± standard deviation, except when otherwise indicated. 
Quantitative data were assessed using the Student’s t-test. A value of 
P<0.05 was considered statistically significant. 
 
  
  40 
7. RESULTS 
 
ETA and ETB expression on T and B cells and on monocytes and 
neutrophils. 
For the first time we show ETA and ETB expression on the surface of 
T and B cells and of monocytes. We have observed receptors 
expression on T cells by flow-cytometry (Figure 5) and we have also 
found the expression of ETA and ETB-coding mRNA in CD4+ T cells 
by reverse transcription-PCR (Figure 6). 
Flow cytometry reveal the presence of surface ETA and ETB on B cells 
and monocytes (Figure 7). 
Neutrophils express both ET-1 receptors as shown by flow cytometry 
(Figura 8) and by reverse transcription-PCR (Figura 9). 
 
Quantification of ETA and ETB expression on T cells and monocytes. 
T and B cells and monocytes of both patients and controls expressed 
ETA and ETB on their surface. We assessed receptor expression on 
these cells referring to ∆MFI, and then we compared numerical data 
using mean (∆MFI or ETA/ETB ratio) ± standard deviation. 
In both patients and controls, T cells and monocytes express ETA 
(patients: ∆MFI=100,61±45,21 and 212,24 ± 64,27 respectively; 
controls: ∆MFI= 110,45 ± 35,89 and 188,4 ± 35,61 respectively) at 
higher levels than ETB (patients: 46,85 ± 29,78 and 91,14 ± 27,44 
respectively; controls: ∆MFI= 49,23 ± 29,16 and 98,74 ± 54,66 
respectively) (p<0,001) (Table III). 
Patients affected by diffuse SSc showed lower levels of ETB on T cells 
than patients affected by limited SSc (28,6±17,9 vs 51,9±31,1) 
(p<0,01); a similar pattern was found on monocytes (74,4±29,6 vs 
97,2±24,5) (p<0,05). 
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There were no significant differences in ETA expression on T cells and 
monocytes in patients with diffuse or limited form (94,8±48,2 vs 
99,1±42,1 and 251,2±116,3 vs 199,3±34,5 respectively) (Table IV). 
No significant correlation regarding ETA or ETB expression was found 
in patients treated or not treated with Bosentan (T cell: ETA: 97,9±52 
vs 102,6±44,3; ETB: 47,9±17,7 vs 47,6±32,3, respectively; Monocytes 
ETA: 240,7±130,6 vs 205,1±34,9; ETB: 89,6±22,9 vs 93,1±27,7) 
(Table V). 
ETA and ETB expression on T cells or monocytes showed no 
correlation with the presence or absence of ischaemic digital ulcers (T 
cell: ETA 121,4±69 vs 98,8±41,6 and ETB 40,8±20,1 vs 48,6±31 
respectively; Monocytes: ETA: 221±4,3 vs 211,3±69,6; ETB: 
80,4±25,3 vs 93,6±27,5) (Table VI). 
Patients with pulmonary arterial hypertension (PAH) showed a lower 
ETB expression on monocytes compared with patients without PAH 
(77,2±23,4 vs 96,9±27,3), especially when we considered the limited 
form of the disease (77,6±17,6 vs 102,3±24,4) (p<0,05) (Table VII). 
Furthermore, limited SSc patients with interstitial lung disease (ILD) 
showed a lower ETA expression on T cells compared with patients 
without ILD (77,8±34,2 vs 111,6±43,9) (p<0,05) (Table VIII). 
ETA is expressed at higher levels than ETB on the surface of B cells of 
both patients treated with Bosentan (ETA: 281.33±43.47 vs ETB: 
161.33±43.97) and untreated patients (ETA: 270.00±28.16 vs ETB: 
171.33±35.47). However, there are significant differences in ETA and 
ETB expression in patients with or without therapy. ETA and ETB 
show the same pattern of expression also in B lymphocytes from 
healthy donors.  
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Quantification of ETA and ETB expression on activated T CD4+ and 
CD8+ cells. 
According to flow cytometry results for T cells, both CD4+ and CD8+ 
T lymphocytes of patients and controls express ETA and ETB on their 
surface. As observed in T cells, we found a higher ETA expression in 
unstimulated CD4+ and CD8+ cells. When activated, by contrast, both 
CD4+ and CD8+ cells reduce ETA and raise ETB expression (Figure 
10).  
 
Cytokine response to ETA- and ETB-stimulation by ET-1 in T CD4+ 
cells. 
Evaluation of the IFN-γ-coding mRNA was performed at 3, 6, 24 and 
48 hours with or without receptor blockers, in T lymphocytes of a 
control and a patient. In CD4+ T cells from the control, incubation 
with ET-1 for 3 hours without receptor blockade showed a decrease in 
IFN-γ-coding mRNA (F.C: -2,14). We observed the same after 6 and 
24 hours' incubation. Cells incubated with ET-1 in the presence of 
ETA blocker alone, or both ETA and ETB receptor blockers result in 
the same decrease in IFN-γ-coding mRNA (Figure 11). After 48 hours 
IFN-γ-coding mRNA increased; IFN-γ-coding mRNA increase is 
greatest in presence of ET-1 and ETB blockade (F.C: -1,17). By 
contrast, using CD4+ T cells obtained from one patient, incubation 
with ET-1, both alone (F.C: -20,72) or in the presence of ETA and ETB 
inhibitors (F.C: -17,62 and -28,46 respectively), lead to a significant 
decrease in IFN-γ-coding mRNA after 3 hours, with a return to the 
baseline value of the IFN-γ-coding mRNA after 6 hours. We also 
investigated transcripts for IL-4 and IL-17 after 3 and 6 hours cells 
culture. After 6 hours incubation with ET-1 alone (F.C: 8,02) or 
together with ETA blockade (F.C: 5,54) or ETA and ETB inhibitors 
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(F.C: 5,21) lead to an increase of IL-4-coding mRNA. Conversely, 
ET-1 together with ETB inhibitor induces a decrease in IL-4-coding 
mRNA (F.C: -1,22) (Figure 12).  
Using CD4+ T cells isolated from a healthy control, we observed that 
after incubation with ET-1 for 3 and 6 hours, IL-17-coding mRNA 
decreases (F.C: -5,22 and -1,07 respectively). The same result was 
obtained when cells were incubated with ET-1 in presence of ETB 
inhibitor or both ETA and ETB blockade (F.C: -4,26 and -19,17 
respectively). In contrast using cells from a patient in the same 
conditions, IL-17-coding mRNA showed a similar decrease after 3 
hours, while after 6 hours using ET-1 alone we observed an increase of 
the transcript (F.C 3,08) (Figure 13).  
IL-6- and IL-10-coding mRNA behaved as IL-17-coding mRNA when 
we considered cells obtained from healthy control. 
We used supernatants of culture of the same cells to evaluate cytokine 
production. In particular after 24 hours of incubation with ET-1, IFN-γ 
was 9.5 times higher than in cell culture without ET-1 (7,6 pg/ml vs 0,8 
pg/ml. IFN-γ levels after selective ETA- or ETB-blockade in presence of 
ET-1 were 1,2 pg/ml and 1,6 pg/ml respectively. By contrast, the 
simultaneous blocking of ETA and ETB, which mimics a Bosentan 
condition in vitro, caused a marked reduction of IFN-γ in supernatants 
and we could not detect the cytokine (Figure 14). We also studied IL-4 
production by CD4+ T cells. After 24 hours of ET-1 incubation IL-4 
was not detectable in the medium culture. Conversely, the production 
of IL-4 increased in the presence of ET-1 and selective inhibition of 
ETA (711,42 pg/ml) in a more significant manner than in the presence 
of ETB receptor blockade (694,47 pg/ml). In the presence of both ETA 
and ETB receptor blockade, the production of IL-4, after 24 hour of 
incubation with ET-1, decreased (682 pg/ml). 
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Cytokine response to ETA- and ETB-stimulation by ET-1 in neutrophils 
The IL-8, TNF-α, MMP-9, VEGF, INF-γ and IL-17 was performed at 
1, 3, and 10 hours with ET-1 or LPS or both ET-1 and LPS on isolated 
neutrophils from a healthy donor buffy coat. 
In neutrophils from the healthy donor buffy coat, the incubation with 
ET-1 only for 1 hour showed a marked increase of MMP-9 (165,11 
ηg/mL). On the contrary, after 1 hour incubation with ET-1 we did not 
observe significant changes in the production of the other cytokines 
studied, compared with the control.  
After 3 hours of incubation with LPS and ET-1 the neutrophils 
production of IL-8 is higher (67,69 pg/mL) than with ET-1 alone (7,69 
pg/mL) or with LPS alone (59,23 pg/mL). As far as MMP-9 concerns,  
no difference was observed after stimulus with both ET-1 and LPS 
(205,59 ηg/mL), or with LPS alone (203,78 ηg/mL).  
The production of TNF-α increased much more by cells incubated for 
10 hours with only ET-1 (23,41 pg/mL) than with both ET-1 and LPS 
(2,05 pg/mL) or with LPS alone (-0,23 pg/mL). After 10 hours the 
incubation with ET-1 alone also increases the production of IL-17 
(3,50 pg/mL) much more than with both ET-1 and LPS (-2,50 pg/mL) 
or with LPS alone (-0,50 pg/mL). After 10 hours of incubation, the 
production of IL-8 and MMP-9 also increased, if the neutrophils were 
stimulated with both ET-1 and LPS (134,62 pg/mL and 220,69 ηg/mL 
respectively) rather than with ET-1 alone (16,62 pg/ml and 63,29 
pg/mL respectively) or with only LPS (93,85 pg/mL and 205,29 
ηg/mL respectively). 
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8. DISCUSSION 
 
ET-1 is a mediator known for its vasoconstrictor effect. In the last few 
years other different effects of ET-1 have been identified: it can play a 
role in inflammation, in cell adhesion, in fibrosis and in angiogenesis. 
All these aspects are important in the pathogenesis of SSc, which 
involves three pivotal components: vascular dysfunction and injury, 
activation of the immune system and increased secretion of collagen 
by fibroblasts. Moreover, in patients with SSc, increased levels of ET-
1 are also found in the plasma, derma and internal organs [93-95]. 
Considering these novel properties of ET-1, ERAs may not only have 
a vasodilator effect, but may also have a role in inflammation, 
although less is known about their potential anti-inflammatory effects. 
Little is known about the expression of ET-1 receptors (ETA and ETB) 
on leukocytes. Some studies report that polymorphonuclear cells and 
dendritic cells express both ETA and ETB [65,66,69,71]. Conflicting 
data are reported in the literature about the expression of ET-1 
receptors in monocytes. Mencarelli et al. observed only ETA-coding 
mRNA expression, in contrast Juergens et al. noticed only ETB-coding 
mRNA expression in monocytes [85,86]. Juergens et al. also 
suggested a proinflammatory role for ETB on 
monocytes/macrophages: its stimulation with ET-1 was correlated 
with an increase of proinflammatory cytokines, able to activate Th1 
response. Consistently with this, blocking ETB with Bosentan reduced 
proinflammatory cytokine production [86]. 
In order to better clarify the role of ET-1 in the immune system, we 
first studied the expression of ETA and ETB on lymphocytes, 
monocytes and neutrophils. We observed that T cells and monocytes 
express both ET-1 receptors. We validated our data in a large cohort 
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of patients and controls, with the aim to better understanding the 
possible correlation of ET-1 receptor surface expression and particular 
clinical features. We confirmed not only that T cells and monocytes 
but also B lymphocytes constitutively express ETA and ETB on their 
surface. Moreover, the expression of ETA was greater than the 
expression of ETB both in patients and controls in T cells and 
monocytes, while for B cells there was no difference in the expression 
of the two receptors between patients and controls.  
Considering that a high ETA/ETB ratio correlates with the extension of 
cutaneous fibrosis in SSc patients and in particular that ETB 
expression was lower in dSSc- rather than lSSc-patients, ETA 
signalling seems to be important in the cutaneous profibrotic effects of 
ET-1. Since a lower ETB expression on monocytes correlated with 
PAH and a lower ETA expression on T cells correlates with ILD, we 
can hypothesize that a different pattern of receptor expression is 
associated with a different response of T cells or monocytes in the 
preferential induction of PAH or ILD. ETA signalling and ETB 
signalling may therefore be characteristic of paricular clinical features. 
Moreover, the higher expression of ETB in patients than in healthy 
controls and its increase in activated T cells, lead to the consideration 
that ETB signalling plays a major role in inflammation. 
In order to evaluate potential receptor modulation in a 
proinflammatory microenvironment, we stimulated T cells with anti-
CD3/CD28 antibody-coated microbeads, which mimic physiological 
stimulation and costimulation of T cells by antigen-presenting cells. 
Since we found a reduction in ETA and an increase in ETB on CD4+ 
and CD8+ T cells, we suppose that once CD4+ and CD8+ T cells are 
in a proinflammatory microenvironment, such as in scleroderma 
active lesion, they may modulate receptor expression in favour of 
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ETB. This observation supports the hypothesis that ETB signalling 
plays a major role in inflammation. These data are also in favour of a 
benefit of a double ET-1 receptors blockage. 
Another point of interest is that ETA and ETB are not up- or down-
regulated with ERA therapy. This supports the clinical observation that 
ERAs induce neither pharmacodynamic nor inverse tolerance, 
although we observed this feature only on T cells and monocytes. It is 
likely, however, that the same happens in vascular cells. 
Furthermore, we investigated how T CD4+ cells respond to ET-1 
stimulus in the presence or absence of the selective blocking of one or 
both receptors.  
We focused our attention on INF-γ and IL-6, a proinflammatory 
cytokine, and IL-4, an antinflammatory cytokine. 
The results, obtained by RT-PCR, on the expression of IFN-γ-coding 
mRNA, show an increase of 2.83 times compared with the basal 
condition, if ETB is stimulated and ETA blocked. ET-1 therefore seems 
to promote Th1 responses through ETB. By blocking both receptors, 
the production of transcripts is reduced by 4 times compared with only 
ETA blockage. In contrast, ET-1 in T cells does not stimulate the 
production of IL-4- and IL-6-coding mRNA. However, in the same 
cells, ET-1 induces a slight increase in transcripts encoding for IL-6, 
while it inhibits the production of IL-4. 
Most of these effects can be attributed to ETB, because this receptor is 
mainly expressed on activated T CD4+ cells. 
By ELISA assay we quantified the levels of IFN-γ released in the 
supernatants by CD4+ T cells. We found that ET-1 causes a 
proinflammatory response by T CD4+ cells. The engagement of both 
ETA and ETB triggered production of IFN-γ in the supernatants 9.5 
times higher than in the basal condition. When both receptors were 
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blocked, which simulates a Bosentan condition in vitro, we found a 
profound reduction in IFN-γ production. Interestingly neither selective 
ETA- nor ETB-stimulation caused a IFN-γ production as high as the 
stimulation of both the receptors; and neither selective ETA- nor ETB-
blockage induced IFN-γ production as low as the blockage of both the 
receptors. These observations support the hypothesis of ETA-ETB 
cross-talk in transductional pathways leading to a pro-inflammatory 
response in CD4+ T cells. Stimulating or blocking both ETA and ETB 
therefore has synergistic effects. Recently, similar observations have 
been noted in scleroderma fibroblasts: blocking both ETA and ETB 
suppressed collagen production more effectively than ETA- or ETB-
selective blockage, with synergistic effects [59]. Considering these 
observations and our results, the blockage of both the receptors seems 
to inhibit inflammation and the consequent fibrosis more than 
selective blockage. 
Finally, we focus our attention on innate immunity. Neutrophils 
participate in the early stages of SSc and contribute to endothelial 
damage, by production of reactive oxygen species, fibroblast 
activation and recruitment of T and B cells. We showed that 
neutrophils express ETA and ETB on their surface. After ET-1 
stimulus we observed an increased production of IL-8, TNF-α, MMP-
9 and IL-17. IL-8, TNF-α and IL-17 are proinflammatory cytokines 
while MMP-9 is a metalloproteinase involved in tissue remodelling. 
So ET-1, through ETA and ETB, can contribute to triggering neutrophil 
activation, which leads to vascular damage. 
If this is the case, Bosentan-therapy would be effective also in early-
stage SSc, when inflammation is prominent and facilitates vascular 
damage progression and evolution into fibrosis. 
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9. CONCLUSION 
 
In conclusion our result suggest that the ET-1 system has an important 
role in inflammation and in fibrosis in SSc patients, especially through 
a combined ETA-ETB signalling. In particular ET-1 can promote the 
activation of neutrophils, which are involved in the early stage of 
sclerodermic lesion. By stimulating ET-1, neutrophils are able to 
produce IL-8, which induces chemotaxis of proinflammatory cells at 
the site of inflammation, and promotes angiogenesis. Neutrophils also 
produce TNF-α and IL-17, two proinflammatory cytokines that 
promote the recruiting of monocyte/macrophages and lymphocytes at 
the site of inflammation. Neutrophils, therefore, in the presence of 
high plasma levels of ET-1, may lead to vascular injury and immune 
system activation, two important aspects in the first phase of SSc 
vascular damage. After neutrophil activation, T cells migrate to the 
site of inflammation, and their response can be modulated by ET-1. 
Initially T cells when activated express high levels of ETB, which 
leads to the production of pro-inflammatory cytokines, such as INF-γ. 
These contribute to the perpetuation of inflammation. In the second 
stage T lymphocytes down-modulate the expression of ETB and 
increase expression of ETA, as we observed in patients with a long 
history of SSc. In this way T cells can promote a profibrotic effect, 
that lead to an increase in collagen and matrix protein production by 
fibroblasts.  
These results pave the way for a more exhaustive study on the role of 
ET-1 in the pathogenetic changes in the immune system in SSc. 
Bosentan may therefore also exert anti-inflammatory effects. 
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10. TABLE AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE I. ET-1, ET-2, ET-3 producing cells [Modified from Khimji AK, Rockey 
DC.: Endothelin, Biology and disease. Cellular Signalling 2010; 22: 1615–1625]. 
 
Endothelin*1, Endothelin*2, Endothelin*3,
Endothelial+cells+ Epithelial+cells+of+the+kidney+ Neuronal+stromal+cells++
Fibroblasts+and+myofibroblasts+ Stromal+cells+of+the+gastrointestinal+tract+ Glial+cells+
Smooth+muscle+cells+on+the+
vasal+wall++ Cardiac+myocytes+ Cells+of+the+adrenal+cortex+
Leukocytes+(mast+cells,+
macrophages,+
polymorphonuclear,+Dendritic+
cells)+
Trophoblast+cells+ Lung+epithelial+cells+
Cardiac+myocytes++ Cellule+epiteliali+dell’epitelio+ghiandolare+dell’utero+
Cellule+epiteliali+della+mucosa+
intestinale+
Epithelial+cells+of+the+kidney+  Epithelial+cells+of+the+kidney+
Mesangial+cells+of+the+kidney+  Epithelial+cells+of+the+intestinal+mucosa 
Astrocytes+   
Neuronal+cells+stromal+   
Epithelial+cells+of+the+breast+   
Endometrial+cells+   
Sertoli+cells+   
Epithelial+cells+of+the+bile+ducts+   
 
 
 
  
TABLE II. Cells expressing ETA and/or ETB, and their main functions [Modified 
from Khimji AK, Rockey DC.: Endothelin, Biology and disease. Cellular 
Signalling 2010; 22: 1615–1625]. 
 
Cells, Receptors, Role,play,
Endothelial+cells+ ETB+ Regulation+of+vascular+tone+
Smooth+muscle+cells+ ETA,+ETB+
Contraction+of+smooth+muscle+of+the+
vassal+wall,+cell+proliferation+
Fibroblasts+and+myofibroblasts+ ETA,+ETB+
Contractility,+synthesis+of+extracellular+
matrix+proteins+
Cardiac+myocytes+ ETA,+ETB+
Cell+proliferation,+contraction,+
hypoxiaJinduced+apoptosis+
Hepatocytes+ ETA,+ETB+
Regulation+of+metabolism+
(glycogenolysis+and+gluconeogenesis)+
Epithelial+cells+of+the+renal+collecting+
ducts+
ET
B+ Tubular+reabsorption+
Neurons+ ETA,+ETB+
Lengthening+of+neurites;+cellular+
response+to+stress+and+apoptosis+
Osteoblasts+ ETA,+ETB+
Proliferation,+differentiation,+synthesis+
of+extracellular+matrix+proteins+
Keratinocytes+ ETA,+ETB+ Proliferation+and+melanogenesis+
Adipocytes+ ETA,+ETB+
Regulation+of+lipid+and+glucose+
metabolism++
Monocytes+/+macrophages+ ETA+[110],+ET+B+[123]+ Inflammations+
PMNs+ ETA+[110],+ET+B+[111]+ Inflammations+
Mast+cells+ ETA+?+[151,152]+ ???+
Platelets+ ETA+[111],+ETB+[153]+
Regulation+of+mechanisms+of+adhesion+
and+platelet+aggregation+
Dendritic+cells+ ETA+[127],+ET+B+[127]+
Regulation+of+maturation,+functions+
and+apoptosis+
 
 
  
Table III. SSc patients vs healthy controls. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
SSc PATIENTS 
T cells 
A   100.6±45.2 
B     46.8±29.8 
monocytes 
A     212.2±64.3 
B     91.1±27.4 
HEALTHY 
CONTROLS 
T cells 
A   110.4±35.9 
B     49.2±29.2 
monocytes 
A     188.4±35.6 
B     98.7±54.7 
 
Table shows differences among SSc patients and healthy controls about ETA and ETB 
expression on T cells and monocytes. ∆MFI (∆ median fluorescence intensity) represents the 
quantification of receptors expression, according to the following equation: ∆MFI= receptor 
MFI - IgG MFI. Receptor MFI represents the MFI of samples incubated with both primary 
anti-receptor and PE-conjugated secondary antibodies. IgG MFI represents the negative 
control, i.e. the MFI of samples incubated only with PE-conjugated secondary antibody. 
ETA/ETB ratio represents the ratio between ETA  ∆MFI and ETB ∆MFI. ∆MFI (for ETA and ETB) 
and ETA/ETB ratio on T cells and monocytes are here reported as mean ± standard deviation 
among samples of patients or controls. 
  
Table IV. dSSc vs lSSc patients. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
dSSc PATIENTS 
T cells A 94.8±48.2 
B 28.6±17.9 
monocytes A 251.2±116.3 
B 74.4±29.6 
lSSc PATIENTS 
T cells A 99.1±42.1 
B 51.9±31.1 
monocytes A 199.3±34.5 
B 97.2±24.5 
 
Table shows differences among dSSc and lSSc patients about ETA and ETB expression 
on T cells and monocytes. 
 
Table V. Bosentan-treated vs Bosentan-free SSc patients. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
BOSENTAN 
TREATED PATIENTS 
T cells 
A   97.9±52 
B     47.9±17.7 
monocytes 
A     240.7±130.6 
B     89.6±22.9 
BOSENTAN FREE 
PATIENTS 
T cells 
A   102.6±44.3 
B     47.6±32.3 
monocytes 
A     205.1±34.9 
B     93.1±27.7 
 
Table shows differences among Bosentan-treated and Bosentan-free SSc patients about 
ETA and ETB expression on T cells and monocytes. 
  
Table VI. SSc patients with vs those without ischemic digital ulcers. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
SSc 
PATIENTS 
WITH DUs 
T cells 
A   121.4±68 
B  
   40.8±20.1 
monocytes 
A  
   221±4.3 
B  
   80.4±25.3 
SSc 
PATIENTS 
WITHOUT 
DUs 
T cells 
A   98.8±41.6 
B  
   48.6±31 
monocytes 
A  
   211.3±69.6 
B  
   93.6±27.5 
 
Table shows differences among SSc patients with or without ischemic digital ulcers 
about ETA and ETB expression on T cells and monocytes. 
 
Table VII. SSc patients with vs those without pulmonary arterial hypertension. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
SSc PATIENTS 
WITH PAH 
T cells 
A   97.3±43.3 
B     44.4±21 
monocytes 
A     229.7±111 
B     77.2±23.4 
SSc PATIENTS 
WITHOUT PAH 
T cells 
A   100.4±44.5 
B     49.1±33.7 
monocytes 
A     206.1±34.7 
B     96.9±27.3 
 
Table shows differences among SSc patients with or without pulmonary arterial 
hypertension about ETA and ETB expression on T cells and monocytes. 
  
Table VIII. SSc patients with vs those without interstitial lung disease. 
 
SAMPLE CELLS RECEPTOR 
 
∆MFI MEAN ± 
STANDARD DEVIATION 
 
SSc PATIENTS 
WITH ILD 
T cells 
A   88.3±43.6 
B     41.6±38.7 
monocytes 
A     224.3±89.5 
B     83.1±30.5 
SSc PATIENTS 
WITHOUT ILD 
T cells 
A   112.4±46.6 
B     52.1±21 
monocytes 
A     202±34.3 
B     97.2±24.5 
 
Table shows differences among SSc patients with or without interstitial lung disease 
about ETA and ETB expression on T cells and monocytes. 
  
 
 
FIGURE 1 [Modified from Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev 
Pathol. 2011;6:509-37]. Pathogenesis of systemic sclerosis. 
  
 
 
 
 
 
 
 
 
FIGURE 2 [Modified from Al-karim Khimji, Don C. Rockey.: Endothelin, Biology and disease. Cellular 
Signalling 2010; 22: 1615–1625]. The ET-1 is formed from the gene encoding the pre-proET-1, which is 
converted first into preET-1 and then in BigET-1 due to cleavage of the protease. The latter is cleaved by 
enzymes, especially ECE-1 or 2, to form the biologically active form of the peptide, namely the ET-1 
  
 
 
FIGURE 3 [Modified from Al-karim Khimji, Don C. Rockey.: Endothelin, Biology and disease. Cellular 
Signalling 2010; 22: 1615–1625]. On the left is shown an endothelial cell, in which the ET-1 triggers, via the 
ETB receptor binding and signal transduction, the production of NO, which induces in the vascular smooth 
muscle cell (shown on the right) relaxation myofibrils. In vascular smooth muscle cell, the ET-1, however, 
through binding to the ETA receptor, has a direct effect of contraction of myofibrils, so that under normal 
conditions the effects of vasoconstriction and vasodilatation are balanced. 
FIGURE 4 [Modified from Al-karim Khimji, Don C. Rockey.: Endothelin, Biology and disease. Cellular 
Signalling 2010; 22: 1615–1625]. In the smooth muscle cell stimulation of ET-1, through binding to the ETA 
receptor, is able to induce two signal transduction pathways which lead respectively to contraction of 
myofibrils and mitogenesis and cell growth. These aspects are particularly important in vascular perturbation 
in SSc. The ETA receptor antagonist ambrisentan specifically interfere with these molecular mechanisms. 
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Figure 5. ETA and ETB expression in T cells and monocytes detected by flow cytometry. Here is shown only 
one paradigmatic case. T cells were selected by locating a gate on CD3+ cells and another on scattering 
features (A). Monocytes were picked out by locating a gate on CD14+ cells and another on scattering 
features (B). The quantification of receptors expression on these cells is represented by the difference of 
fluorescence intensity between sample (red line) and its negative control (black line).  
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FIGURE 6. Agarose gel electrophoretic separation of amplicons ETA and ETB. The amplification 
reaction occurred starting from the cDNA obtained from CD4+ lymphocytes, at basal and after 
stimulation with CD3/CD28, and fibroblasts. The amplification of the cDNA encoding vimentin 
(housekeeping gene) is the control of the method of RT-PCR. Fibroblasts are a positive control for 
the expression of the ETA and ETB. The CD4+ T cell express ETA and ETB. 
 
 
  
 
 
 
ETA ETB 
Negative control Negative control 
C
el
l n
um
be
r  
C
el
l n
um
be
r  
Figure 7. ETA and ETB expression in B cells by flow cytometry. 
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Figure 8. ETA and ETB expression in neutrophil by flow cytometry. 
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FIGURE 9. Agarose gel electrophoretic separation of amplicons ETA and ETB. The amplification 
reaction occurred starting from the cDNA obtained from neutrophils. Fibroblasts are a positive 
control for the expression of the ETA and ETB. Neutrophil express ETA and ETB. 
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Figure 10. Change in ETA and ETB expression on activated T CD4+ and CD8+ cells. The stimulation 
of cells, performed with microbeads coated by anti-CD3/CD28 antibodies, leads to a reduction of ETA 
and a raise of ETB expression, both in CD4+ (A) and CD8 cells (B). Here is shown only one of four 
similar experiments. 
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Figure 11. INF-γ, RT-PCR. The IFN-γ-coding mRNA was performed at 3, 6, 24 and 48 hours with or without 
receptor blockers, on T lymphocytes of a control. 
Figure 12. IL-4, RT-PCR at 6 hours. After 6 hours incubation with ET-1 alone (F.C: 8,02) or together with ETA 
blockade (F.C: 5,54) or ETA and ETB inhibitors (F.C: 5,21) lead to an increase of IL-4-coding mRNA. Conversely ET-1 
together with ETB inhibitor induces a decrease of IL-4-coding mRNA (F.C: -1,22). 
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Figure 13. Using CD4+ T cell isolated  from healthy control, we observed that after incubation with 
ET-1 for 3 and 6 hours IL-17-coding mRNA decrease. The same was obtained when cells were 
incubated with ET-1 in presence of ETB inhibitor or both ETA and ETB blockade. In contrast using 
cells from patient in the same conditions, IL-17-coding mRNA showed similar decrease after 3 hours 
while after 6 hours using ET-1 alone we observed an increase of the transcript (F.C 3,08). 
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Figure 14. Proinflammatory response to ETA and ETB stimulation with ET-1 in T CD4+ cells. Figure shows 
IFN-γ production by T CD4+ cells in 5 different conditions: basal condition (1), ETA and ETB stimulation 
with ET-1 (2), ETA blockage with BQ123 and ETB stimulation with ET-1 (3), ETB blockage with BQ788 
and ETA stimulation with ET-1 (4), blockage of both ETA and ETB and stimulation with ET-1. IFN-γ 
production in the supernatants of plates was measured in pg/ml and assessed on the basis of a standard 
curve of IFN-γ concentrations, from 0 to 1000 pg/ml. IFN-γ productions resulted: 0,8 pg/ml in condition 1; 
7,6 pg/ml in condition 2; 1,6 pg/ml in condition 3; 1,2 pg/ml in condition 4; less than measurable in this 
system in condition 5. In condition 2, when both ETA and ETB were stimulated with ET-1, IFN-γ 
production was 9,5 times higher than basal condition. Synergic effects were observed both for the 
stimulation and the blockage of ETA and ETB. 
 
